Welcome to our dedicated page for Atrion Corporation news (Ticker: $ATRI), a resource for investors and traders seeking the latest updates and insights on Atrion Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atrion Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atrion Corporation's position in the market.
Atrion (NASDAQ: ATRI) has entered into a merger agreement with Nordson Nordson will acquire Atrion for $460 per share in cash, valuing the deal at approximately $815 million. This price represents a 15% premium to Atrion’s 90-day average stock price and is 20.2 times Atrion’s 2023 EBITDA. The transaction was unanimously approved by the boards of both companies and is expected to close in Q3 2024, pending customary regulatory approvals and closing conditions.
Three of Atrion’s largest shareholders, representing 22% of the company’s shares, have agreed to vote in favor of the merger. Truist Securities is the financial advisor for Atrion, and A&O Shearman is the legal counsel. Upon completion, Atrion will become a wholly-owned subsidiary of Nordson.
Nordson (Nasdaq: NDSN) announced its agreement to acquire Atrion (Nasdaq: ATRI), a leader in medical infusion and cardiovascular technologies, for $460.00 per share in cash. This acquisition values Atrion at approximately $800 million and expands Nordson’s medical portfolio into new markets and therapies. Atrion generated about $169 million in revenue in 2023 and operates three FDA registered manufacturing facilities in the U.S.
The acquisition will be funded through cash on hand and newly issued financial debt and is expected to close before Nordson’s fiscal year-end in 2024, pending regulatory and stockholder approvals. The transaction is expected to generate significant synergies within the first two years of ownership.
The acquisition aligns with Nordson's strategy to leverage long-term growth drivers in the medical sector, including an aging population, increased healthcare spending, and the adoption of minimally invasive surgical techniques.
Atrion (NASDAQ: ATRI) has announced a quarterly dividend of $2.20 per share on its common stock. This dividend will be paid on June 28, 2024, to shareholders recorded by June 14, 2024. Atrion specializes in developing and manufacturing medical products.
Atrion (NASDAQ: ATRI) reported first quarter 2024 results with revenues of $47.3 million, operating income of $3.1 million, and net income of $2.8 million. Diluted earnings per share were $1.59. Despite revenue growth and increased operating income, net income decreased due to a one-time inventory write-off. Gross margins declined primarily due to delayed orders, excess inventory, and product mix. The company remains debt free with total cash and investments of $18.7 million.